A Gupta1, D Monroy, Z Ji, K Yoshino, A Huang, S C Pflugfelder. 1. Ocular Surface and Tear Center, Bascom Palmer Eye Insitute, Department of Ophthalmolgy, University of Miami School of Medicine, Miami, Florida 33136, USA.
Abstract
PURPOSE: To evaluate human tear fluid for transforming growth factor beta isoforms 1 and 2 (TGF-beta1 and TGF-beta2). METHODS: To accomplish this, human tears were evaluated for TGF-betas by quantitative antibody sandwich ELISA (sELISA), mink lung epithelial cell (MLEC) growth inhibition bioassay and western blotting. Various physical and chemical treatments were used to activate TGF-beta in these assays. RESULTS: TGF-betas could not be detected in untreated or heated tears by sELISA; however, mean TGF-beta1 concentrations of 2.32 ng/ml were detected in acid-activated tears by sELISA. Furthermore, 10.54 ng/ml of TGF-beta1 and 2.98 ng/ml of TGF-beta2 were detected in tears treated with the mucolytic agent, acetylcysteine. Total TGF-beta bioactivity in human tears measured by the MLEC assay was found to be 13.04 ng/ml in untreated tears and 24.85 ng/ml in acid-activated tears. Approximately one-half TGF-beta in tear specimens was biologically active (mean = 52%, range 39-71%). Total tear TGF-beta bioactivity could be completely neutralized by recombinant human TGF-beta1 latency associated peptide (rh TGF-beta1 LAP). Mean neutralization of tear TF-beta bioactivity was 83% by TGF-beta1-specific antisera, and was 13% by TBF-beta2-specific antisera. Immunoreactive TBF-beta bands at approximately 12.5 and 95 kD were observed in immunoblots of reduced acidified tears. A high molecular weight (MW) TGF-beta band (>203 dD) was noted in untreated tears; however, this band disappeared following treatment with acetylcysteine. CONCLUSIONS: The results of these studies indicate that TGF-beta1 and TGF-beta2 are present in human tear fluid, and TGF-beta1 is the predominant isoform. There appear to be factors in human tears capable of binding TGF-beta.
PURPOSE: To evaluate human tear fluid for transforming growth factor beta isoforms 1 and 2 (TGF-beta1 and TGF-beta2). METHODS: To accomplish this, human tears were evaluated for TGF-betas by quantitative antibody sandwich ELISA (sELISA), mink lung epithelial cell (MLEC) growth inhibition bioassay and western blotting. Various physical and chemical treatments were used to activate TGF-beta in these assays. RESULTS: TGF-betas could not be detected in untreated or heated tears by sELISA; however, mean TGF-beta1 concentrations of 2.32 ng/ml were detected in acid-activated tears by sELISA. Furthermore, 10.54 ng/ml of TGF-beta1 and 2.98 ng/ml of TGF-beta2 were detected in tears treated with the mucolytic agent, acetylcysteine. Total TGF-beta bioactivity in human tears measured by the MLEC assay was found to be 13.04 ng/ml in untreated tears and 24.85 ng/ml in acid-activated tears. Approximately one-half TGF-beta in tear specimens was biologically active (mean = 52%, range 39-71%). Total tear TGF-beta bioactivity could be completely neutralized by recombinant humanTGF-beta1 latency associated peptide (rh TGF-beta1LAP). Mean neutralization of tear TF-beta bioactivity was 83% by TGF-beta1-specific antisera, and was 13% by TBF-beta2-specific antisera. Immunoreactive TBF-beta bands at approximately 12.5 and 95 kD were observed in immunoblots of reduced acidified tears. A high molecular weight (MW) TGF-beta band (>203 dD) was noted in untreated tears; however, this band disappeared following treatment with acetylcysteine. CONCLUSIONS: The results of these studies indicate that TGF-beta1 and TGF-beta2 are present in human tear fluid, and TGF-beta1 is the predominant isoform. There appear to be factors in human tears capable of binding TGF-beta.
Authors: Xiaofen Zheng; Cintia S De Paiva; Kavita Rao; De-Quan Li; William J Farley; Michael Stern; Stephen C Pflugfelder Journal: Cornea Date: 2010-09 Impact factor: 2.651
Authors: Niral B Gandhi; Zhitao Su; Xiaobo Zhang; Eugene A Volpe; Flavia S A Pelegrino; Salman A Rahman; De-Quan Li; Stephen C Pflugfelder; Cintia S de Paiva Journal: J Leukoc Biol Date: 2013-08-27 Impact factor: 4.962
Authors: Hui Qi; Shrestha Priyadarsini; Sarah E Nicholas; Akhee Sarker-Nag; Jeremy Allegood; Charles E Chalfant; Nawajes A Mandal; Dimitrios Karamichos Journal: J Lipid Res Date: 2017-02-10 Impact factor: 5.922
Authors: Cintia S De Paiva; Cindy S Hwang; John D Pitcher; Solherny B Pangelinan; Ehsan Rahimy; Wei Chen; Kyung-Chul Yoon; William J Farley; Jerry Y Niederkorn; Michael E Stern; De-Quan Li; Stephen C Pflugfelder Journal: Rheumatology (Oxford) Date: 2009-12-09 Impact factor: 7.580